Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small Cell Lung Cancer: early-phase trial registry
206 of 455 indexed Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #10 of 28,707 conditions by registered trial count.
455 US clinical trials · 206 currently recruiting · #10 of 28,707 conditions by registered trial count
Non-Small Cell Lung Cancer: 455 US clinical trials tracked, 206 recruiting.
Non-Small Cell Lung Cancer is the subject of 455 registered US clinical trials on ClinicalTrials.gov, 206 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 24 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer
OPEN 206 | RECR 45% | LATE 65 | EARLY 327 | RANK #10 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Non-Small Cell Lung Cancer lists 206 open slots (45% of 455 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small Cell Lung Cancer is recruiting above its size-band peers.
206 of 455 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Small Cell Lung Cancer trials is spread across many organizations.
AstraZeneca accounts for 24 of 455 trials (5.3%). 242 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Small Cell Lung Cancer enrolment sits around 105 participants.
Median target enrolment is 105 among the 455 trials that report a genuine target (sentinel values excluded). 212 of those (46.6%) plan for fewer than 100 participants.
-
Non-Small Cell Lung Cancer research is mostly interventional.
414 interventional and 41 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
455 total, page 4 of 10
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
NCT07064018
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
VA Office of Research and Development
NCT05467748
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Teligene US
NCT06010329
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
M.D. Anderson Cancer Center
NCT06919874
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT07218601
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Ankyra Therapeutics
NCT07027514
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Karen Reckamp, MD, MS
NCT05401110
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07115043
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
BioNTech SE
NCT06841055
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Abramson Cancer Center at Penn Medicine
NCT04332367
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT06007937
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
University of California, Davis
NCT07250477
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
H. Lee Moffitt Cancer Center and Research Institute
NCT06337552
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Obsidian Therapeutics
NCT06060613
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Maximilian Diehn
NCT04585490
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med
NCT05283330
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT05877599
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
University of Nebraska
NCT06579196
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Virginia Commonwealth University
NCT06731413
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Wayshine Biopharm
NCT06868485
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
NCT05431270
Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers
M.D. Anderson Cancer Center
NCT07234799
Phase 2 Study of Fingolimod in Lung Cancers
Medical University of South Carolina
NCT06424067
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
NYU Langone Health
NCT07249372
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Yale University
NCT04210492
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
Medical College of Wisconsin
NCT06305715
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
InSightec
NCT05317858
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Tumor Treating Fields for Locally Advanced NSCLC
University of Utah
NCT06124118
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Ryan Gentzler, MD
NCT06248606
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
University of Miami
NCT06902272
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT07133425
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
University of Rochester
NCT04297605
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
NCT05837767
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Diwakar Davar
NCT05669846
Repositioning Immunotherapy in VetArans With Lung Cancer
VA Office of Research and Development
NCT06275360
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Memorial Sloan Kettering Cancer Center
NCT07323732
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Brown University
NCT04933903
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05620342
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
University of Alabama at Birmingham
NCT06364917
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Icahn School of Medicine at Mount Sinai
NCT06088771
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Jordan Kharofa
NCT07225036
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
University of California, Davis
NCT05452005
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
Wake Forest University Health Sciences
NCT06567704
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
University of Maryland, Baltimore
NCT06800339
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT07428044
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 203 |
| Phase 2 | 124 |
| Phase 3 | 62 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small Cell Lung Cancer page
455 registered trials, 206 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 206 Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small Cell Lung Cancer condition card totals 455 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.